Cardiovascular Today—April 23, 2026

LucidQuest

3 hours ago

This week’s Cardiovascular update highlights regulatory clearances, late-stage clinical progress, imaging advances, strategic deals, and new real-world evidence across interventional care and prevention.

In Today’s Newsletter

Dive deeper

🫀 Protaryx Medical wins US clearance for transseptal access [1] [US • 15 Apr 2026]

https://cardiovascularnews.com/protaryx-medical-receives-us-fda-clearance-for-proprietary-transseptal-puncture-device/
Context: Protaryx Medical received US FDA 510(k) clearance for a transseptal puncture device intended for left atrial access in LAAC, transcatheter mitral procedures, and AF ablation.
Key point: The company positions the catheter system as a safer, more accurate, and more reproducible approach to transseptal puncture; an early first-in-human study reported procedural success in all five cases with no device-related adverse events. Implication: May influence prescriber choice and payer reviews pending full data.

🧠 Elucid adds lesion-level plaque analysis to Plaque-IQ [2] [US • 16 Apr 2026]

https://cardiovascularnews.com/elucid-launches-lesion-inspection-tool-for-coronary-and-carotid-plaque-analysis/
Context: Elucid launched a Lesion Inspection Tool within Plaque-IQ for coronary and carotid plaque analysis, using CT-Virtual Histology to quantify plaque composition non-invasively.
Key point: The new tool lets clinicians interrogate lesion-specific plaque burden and composition, including lipid-rich necrotic core, rather than relying only on whole-vessel metrics.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💊 Bayer publishes full OCEANIC-STROKE results for asundexian [3] [17 Apr 2026]

https://www.pharmabiz.com/NewsDetails.aspx?aid=185418&sid=2
Context: Bayer reported full Phase III OCEANIC-STROKE results for asundexian, a once-daily oral FXIa inhibitor, in 12,327 patients after non-cardioembolic ischemic stroke or high-risk TIA.
Key point: The source says asundexian reduced ischemic stroke by 26% versus placebo, with no increase in ISTH major bleeding, and also improved multiple net clinical benefit composites.
Implication: May influence prescriber choice and payer reviews pending full data.

🤖 Stereotaxis moves to acquire Robocath [4] [EU • 16 Apr 2026]

https://cardiovascularnews.com/stereotaxis-to-acquire-robocath/
Context: Stereotaxis entered a definitive agreement to acquire Robocath, whose R-One+ robotic PCI platform is commercially available in Europe; Robocath is also developing a next-generation system.
Key point: The deal combines complementary robotic platforms across interventional cardiology and neurointerventions, with Stereotaxis targeting future US and EU regulatory submissions for Robocath’s next-generation system.
Implication: Signals pipeline investment and modality expansion.

🏥 Medtronic expands with CathWorks and Pulnovo [5] [20 Apr 2026]

https://cardiovascularnews.com/medtronic-completes-cathworks-acquisition-and-invests-in-pulnovo/
Context: Medtronic completed its CathWorks acquisition and made a leading investment in Pulnovo Medical as part of Pulnovo’s US$100 million financing round.
Key point: CathWorks adds FFRangio, a wire-free, AI-enabled coronary physiology platform, while Pulnovo adds exposure to pulmonary artery denervation for pulmonary hypertension and heart failure.
Implication: Signals pipeline investment and modality expansion.

🔎 Conavi clears US FDA hurdle for hybrid IVUS-OCT imaging [6] [US • 20 Apr 2026]

https://cardiovascularnews.com/us-fda-grants-510k-clearance-for-hybrid-coronary-imaging-system/
Context: Conavi Medical received US FDA 510(k) clearance for a next-generation coronary imaging platform that combines IVUS and OCT in one system.
Key point: The company says the hybrid platform is designed to provide deep-vessel and high-resolution surface imaging in real time, with a US commercial launch planned for the second half of 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

📊 Sirolimus- and paclitaxel-coated balloons show similar 1-year PCI outcomes [7] [21 Apr 2026]

https://cardiovascularbusiness.com/topics/clinical/interventional-cardiology/sirolimus-and-paclitaxel-coated-balloons-deliver-comparable-1-year-pci-outcomes
Context: A JSCAI real-world registry analysis in Sweden included more than 8,000 PCI patients treated from 2022 to 2025, comparing paclitaxel-coated balloons and sirolimus-coated balloons.
Key point: After one year, no statistical differences were reported for target segment revascularization, target vessel revascularization, restenosis, myocardial infarction, repeat PCI, or all-cause mortality, despite lower in-stent restenosis with paclitaxel-coated balloons.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💉 Evolocumab subgroup data point to earlier prevention in diabetes [8] [21 Apr 2026]

https://cardiovascularbusiness.com/topics/clinical/pharmaceutics/evolocumab-reduces-risk-major-cardiac-events-diabetic-patients
Context: A late-breaking subgroup analysis of VESALIUS-CV examined diabetic patients without known atherosclerosis, representing about 30% of trial participants, over roughly 4.5 years.
Key point: The source reports that evolocumab reduced both primary MACE endpoints by 31%, with additional reductions in cardiovascular death and nominal all-cause mortality, when added to statin therapy.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Cardiovascular medtech deal flow remained active, with Stereotaxis, Medtronic, and Pulnovo highlighting continued interest in robotics, physiology imaging, and denervation platforms [4][5].
US FDA clearances for Protaryx and Conavi show continued momentum in procedural tools and intravascular imaging, especially where workflow simplification is part of the value proposition [1][6].
Bayer’s asundexian update keeps FXIa inhibition in focus for secondary stroke prevention, with publication in a major journal adding visibility and clinical credibility [3].
Imaging and analytics continue to move toward lesion-level and multimodal decision support, as shown by Elucid’s plaque software update and CathWorks’ FFRangio platform [2][5].
Clinical practice signals remain mixed but useful, with real-world balloon registry data and evolocumab subgroup findings offering near-term discussion points for interventionalists, lipid specialists, and payers [7][8].
.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Cardiovascular archive on our research hub page

🎯 Catch up on the Top Cardiovascular news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What was cleared for Protaryx Medical? [1]

Protaryx Medical received US FDA 510(k) clearance for a proprietary transseptal puncture device. The source says it is intended to improve left atrial access for LAAC, mitral interventions, and AF ablation [1].

What is new in Elucid’s Plaque-IQ platform? [2]

Elucid added a Lesion Inspection Tool for coronary and carotid plaque analysis. It is designed to quantify lesion-specific plaque composition, including lipid-rich necrotic core, within the Plaque-IQ software suite [2].

What did Bayer report for asundexian in OCEANIC-STROKE? [3]

Bayer said full Phase III results were published in The New England Journal of Medicine. The source reports a 26% reduction in ischemic stroke and no increase in ISTH major bleeding versus placebo on top of antiplatelet therapy [3].

Why does the Stereotaxis-Robocath deal matter? [4]

The acquisition adds Robocath’s robotic PCI and neurointervention technology to Stereotaxis’ broader endovascular robotics strategy. The companies also pointed to future regulatory work in the US and Europe for the next-generation system [4].

What did Medtronic gain from CathWorks and Pulnovo? [5]

CathWorks adds FFRangio, a wire-free coronary physiology platform, to Medtronic’s interventional cardiology portfolio. Pulnovo gives Medtronic a strategic foothold in pulmonary artery denervation for pulmonary hypertension and heart failure [5].

What should readers take from the evolocumab subgroup analysis? [8]

The subgroup analysis suggests benefit in diabetic patients without known atherosclerosis, a population not usually treated with advanced lipid-lowering therapy. The report is encouraging, but it is still a subgroup analysis rather than a standalone dedicated outcomes trial [8].

Entities / Keywords

Cardiovascular medtech, interventional cardiology, stroke prevention, structural heart, electrophysiology, transseptal puncture, Protaryx Medical, US FDA 510(k), Elucid, Plaque-IQ, CT-Virtual Histology, coronary plaque, carotid plaque, Bayer, asundexian, FXIa inhibitor, OCEANIC-STROKE, NEJM, Stereotaxis, Robocath, R-One+, robotics, PCI, neurointerventions, Medtronic, CathWorks, FFRangio, Pulnovo Medical, pulmonary artery denervation, PADN, Conavi Medical, IVUS, OCT, hybrid imaging, sirolimus-coated balloon, paclitaxel-coated balloon, JSCAI, evolocumab, PCSK9 inhibitor, VESALIUS-CV, LDL lowering.